Matthew A. Cavender, MD, MPH, FACC

Assistant Professor of Medicine, Division of Cardiology
Co-Director of Cardiology Clinical Trials

Specialty Areas: Interventional cardiology; Aortic and Mitral Valve Disease; Coronary Artery Disease; Cardiogenic Shock/Hemodynamic Support Devices; Atrial Septal Defect, Patent Foramen Ovale; Peripheral Vascular Disease.

Chronology:

MD: University of Alabama School of Medicine (2006)

Master’s of Public Health: Harvard School of Public Health (2013)

Internship/Residency: Internal Medicine, Duke University Medical Center (2006-2009)

Fellowship: Cardiovascular Medicine, Cleveland Clinic (2009-2012)

Post-Doctoral Research Fellowship: TIMI Study Group, Brigham and Women’s Hospital, Harvard Medical School, Cardiovascular Medicine (2012-2016)

Advanced Clinical Fellowship: Interventional Cardiology, Brigham and Women’s Hospital, Harvard Medical School (2014-2015)

Advanced Clinical Fellowship: Valvular Heart Disease and Peripheral Vascular Interventions, Brigham and Women’s Hospital, Harvard Medical School (2015-2016)

Assistant Professor of Medicine: University of North Carolina (2016)

Board Certifications:

Internal Medicine (2009)
Cardiovascular Disease (2012)
Interventional Cardiology (2015)

Dr. Cavender is an active interventional cardiologist with a focus on catheter based interventions for coronary artery disease, aortic and mitral valve disease, peripheral vascular disease, and cardiogenic shock. In addition to his clinical interests, he has an active research program with an emphasis on improving the quality of health care delivery and understanding the clinical effectiveness of pharmacological and device based therapies for patients with coronary artery disease, diabetes, peripheral arterial disease, and valvular heart disease.

Selected Bibliography:

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M; CVD-REAL Investigators and Study Group. J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506.

Total Cardiovascular Events Analysis of the EXAMINE Trial in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. Cavender MA, White WB, Liu Y, Massaro JM, Bergenstal RM, Mehta CR, Zannad F, Heller S, Cushman WC, Cannon CP. Clin Cardiol. 2018 Apr 13. doi: 10.1002/clc.22960. [Epub ahead of print]

Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. Cavender MA, Bhatt DL, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Elkin S, Deliargyris EN, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators*. Circ Cardiovasc Interv. 2017 Aug;10(8). pii: e005257.

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Circulation. 2017 Jul 18;136(3):249-259.

Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial. Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Circulation. 2017 May 16;135(20):1911-1921.

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA; CHAMPION PHOENIX Investigators. Circulation. 2016 Sep 6;134(10):723-33.

Is It Time for Radial Access to Become a Quality Metric for Percutaneous Coronary Intervention? Cavender MA, Kaul P. Circ Cardiovasc Interv. 2016 May;9(5):e003881.

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. O’Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA; LATITUDE-TIMI 60 Investigators. JAMA. 2016 Apr 19;315(15):1591-9.

Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction. Wang TY, McCoy LA, Bhatt DL, Rao SV, Roe MT, Resnic FS, Cavender MA, Messenger JC, Peterson ED. Am Heart J. 2016 Feb;172:9-18.

Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. Boyden TF, Joynt KE, McCoy L, Neely ML, Cavender MA, Dixon S, Masoudi FA, Peterson E, Rao SV, Gurm HS. Am Heart J. 2015 Dec;170(6):1227-33.

Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. Cavender MA, Scirica BM, Raz I, Steg PG, McGuire DK, Leiter LA, Hirshberg B, Davidson J, Cahn A, Mosenzon O, Im K, Braunwald E, Bhatt DL. Am J Med. 2016 Mar;129(3):340.e1-8.

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators. Circulation. 2015 Oct 13;132(15): e198.

Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg G, Bhatt DL. Circulation. 2015 Aug 11;132(6):e121-2.

Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL; REACH Registry Investigators. Circulation. 2015 Sep 8;132(10):923-31.

Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. O’Donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P, Sabatine MS, Morrow DA. Am Heart J. 2015 May;169(5):622-630

State mandated public reporting and outcomes of percutaneous coronary intervention in the United States. Cavender MA, Joynt KE, Parzynski CS, Resnic FS, Rumsfeld JS, Moscucci M, Masoudi FA, Curtis JP, Peterson ED, Gurm HS. Am J Cardiol. 2015 Jun 1;115(11):1494-501.

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Lancet Diabetes Endocrinol. 2015 May;3(5):356-66.

Can BRIGHT restore the glow of bivalirudin? Cavender MA, Faxon DP. JAMA. 2015 Apr 7;313(13):1323-4.

Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Circulation. 2015 Mar 24;131(12):1047-53.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators. Diabetes Care. 2015 Apr;38(4):696-705.

The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 – TIMI 51 trial. Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchástegui M, Oude Ophuis T, van Hessen M, Mega JL. Eur Heart J Acute Cardiovasc Care. 2015 Oct;4(5):468-74

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators*. Circulation. 2014 Oct 28;130(18):1579-88.

Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Cavender MA, Sabatine MS. Lancet. 2014 Aug 16;384(9943):599-606.

Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? Bhatt DL, Cavender MA. JACC Heart Fail. 2014 Dec;2(6):583-5.

Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors’ reply. Cavender MA, Rassi AN, Schwamm LH, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Bhatt DL. Clin Cardiol. 2014 May;37(5):323.

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators. JAMA. 2014 Jan 15;311(3):252-62.

Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. Cavender MA, Rassi AN, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Schwamm LH, Bhatt DL. Clin Cardiol. 2013 Dec;36(12):749-56.

Patient and hospital characteristics associated with inappropriate percutaneous coronary interventions. Chan PS, Rao SV, Bhatt DL, Rumsfeld JS, Gurm HS, Nallamothu BK, Cavender MA, Kennedy KF, Spertus JA. J Am Coll Cardiol. 2013 Dec 17;62(24):2274-81.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. N Engl J Med. 2013 Oct 3;369(14):1317-26.

Outcomes of culprit versus multivessel PCI in patients with multivessel coronary artery disease presenting with ST-elevation myocardial infarction complicated by shock. Cavender MA, Rajeswaran J, DiPaola L, Houghtaling P, Kiernan MS, Rassi AN, Menon V, Whitlow PW, Ellis SG, Shishehbor MH. J Invasive Cardiol. 2013 May;25(5):218-24.

Are all clinical trial sites created equal? Bhatt DL, Cavender MA. J Am Coll Cardiol. 2013 Feb 5;61(5):580-1. doi: 10.1016/j.jacc.2012.10.024. Epub 2012 Dec 12.

Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DL. J Am Coll Cardiol. 2013 Jan 8;61(1):35-40.

Stent choice and the hidden consequences of cost savings. Cavender MA, Ellis SG. Nat Rev Cardiol. 2012 Oct;9(10):559-60.

Safety of “bridging” with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. Rassi AN, Blackstone E, Militello MA, Theodos G, Cavender MA, Sun Z, Ellis SG, Cho L. Am J Cardiol. 2012 Aug 15;110(4):485-90.

Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Cardiovasc Drugs Ther. 2012 Feb;26(1):71-5

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Cavender MA, Lincoff AM. Am J Cardiovasc Drugs. 2010;10(4):209-16.

Strategies for the development of new PPAR agonists in diabetes. Cavender MA, Nicholls SJ, Lincoff AM. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S32-7.

Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms? Cavender MA, Rao SV. J Thromb Thrombolysis. 2010 Oct;30(3):332-9.

Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease. Cavender MA, Alexander KP, Broderick S, Shaw LK, McCants CB, Kempf J, Ohman EM. Am Heart J. 2009 Dec;158(6):933-40.

Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Am J Cardiol. 2009 Aug 15;104(4):507-13

What do you need to know before performing a percutaneous coronary intervention? Cavender MA, Ohman EM. Circulation. 2008 Aug 5;118(6):609-11.

Major bleeding: management and risk reduction in acute coronary syndromes. Cavender MA, Rao SV, Ohman EM. Expert Opin Pharmacother. 2008 Aug;9(11):1869-83.

Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern. Benza RL, Cavender MA, Barchue J, Tallaj JA, Bourge RC, Kirklin JK, Coffey CS. J Heart Lung Transplant. 2007 May;26(5):494-7.

Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. Benza RL, Anderson PG, Lyle K, Barchue J, de Oliveira AL, Cavender MA, Pinderski LJ, George JF. J Heart Lung Transplant. 2003 May;22(5):515-8.